Mesa Laboratories, Inc. (NASDAQ:MLAB) CEO Gary M. Owens Sells 1,939 Shares

Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) CEO Gary M. Owens sold 1,939 shares of the firm's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $97.12, for a total value of $188,315.68. Following the transaction, the chief executive officer now owns 45,824 shares in the company, valued at approximately $4,450,426.88. This represents a 4.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Mesa Laboratories Stock Up 3.0%

Mesa Laboratories stock traded up $2.83 during trading hours on Friday, reaching $95.82. The stock had a trading volume of 244,290 shares, compared to its average volume of 45,991. The company has a market cap of $523.18 million, a price-to-earnings ratio of -258.97 and a beta of 0.88. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.63 and a quick ratio of 0.47. The business's 50 day moving average price is $110.56 and its 200-day moving average price is $124.85. Mesa Laboratories, Inc. has a 52 week low of $83.68 and a 52 week high of $155.12.

Mesa Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 16th. Stockholders of record on Friday, May 30th were paid a dividend of $0.16 per share. The ex-dividend date of this dividend was Friday, May 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.67%. Mesa Laboratories's payout ratio is -172.97%.

Institutional Investors Weigh In On Mesa Laboratories

A number of large investors have recently modified their holdings of the business. State of Wyoming boosted its position in Mesa Laboratories by 501.4% in the first quarter. State of Wyoming now owns 427 shares of the medical instruments supplier's stock valued at $51,000 after buying an additional 356 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Mesa Laboratories in the first quarter valued at approximately $67,000. Amundi boosted its position in Mesa Laboratories by 81.6% in the 4th quarter. Amundi now owns 661 shares of the medical instruments supplier's stock worth $91,000 after purchasing an additional 297 shares in the last quarter. Resona Asset Management Co. Ltd. purchased a new stake in Mesa Laboratories in the 4th quarter worth approximately $92,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Mesa Laboratories in the 4th quarter worth approximately $132,000. Hedge funds and other institutional investors own 90.60% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Wall Street Zen lowered Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 30th. Wells Fargo & Company cut their price target on Mesa Laboratories from $120.00 to $100.00 and set an "underweight" rating on the stock in a research note on Friday, May 30th.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.